×
0 0 0 0 0 0 0 0
Stockreport

Your Daily Pharma Scoop: Biohaven In Pivotal Stage, Merck Trial Positive, FDA Waives EyeGate [Seeking Alpha]

BIOHAVEN PHARMACEUTICALS HOLDING CO LTD (BHVN)  More Company Research Source: Seeking Alpha
Last biohaven pharmaceuticals holding co ltd earnings: 8/14 04:15 pm Check Earnings Report
US:NYSE Investor Relations: investors.biohavenpharma.com
PDF Summary Biohaven launches Phase 2/3 study of trigriluzole in Alzheimer's Discussion : Biohaven Pharmaceutical Holding Company ( BHVN ) commences Phase 2/3 trial of its candidate BHV-4157 (trigriluzole) in patients with mild-to-moderate Alzheimer's disease (‘AD). Patient enrollment is expected to begin shortly. Following details of the study plan have been shared by the company. During the 48-week trial period, the 292-subject study will be randomized between trigriluzole and placebo. As a potential modulator of an excitatory neurotransmitter trigriluzole is expected to neuroprotective effects at the synaptic level. The company expects this neuroprotective effect not only to improve synaptic function but also to produce disease-modifying effects in AD. The same drug is also indicated for another Phase 2/3 trial for obsessive compulsive disorder. We have previously covered this CNS-focused company with a strong pipeline including multiple drug candidates in late stage [Read more]

IMPACT SNAPSHOT EVENT TIME: BHVN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
BHVN alerts
from News Quantified
Opt-in for
BHVN alerts

from News Quantified
Opt-in for
BHVN alerts

from News Quantified